SOURCE: La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company

February 14, 2013 08:00 ET

La Jolla Pharmaceutical Company Receives Additional Notice of Allowance for Patent Covering Modified Pectin Compositions

SAN DIEGO, CA--(Marketwire - Feb 14, 2013) - La Jolla Pharmaceutical Company (OTCQB: LJPC) ("La Jolla" and "Company"), a leader in the development of therapeutics targeting galectin proteins, announced today that the United States Patent and Trademark Office (USPTO) has issued an additional notice of allowance for claims covering its lead product candidate, GCS-100, from patent application number 13/588,877. The claims, which expire in 2025 without accounting for any potential patent term extension, provide proprietary protection for solutions comprised of purified modified pectin, with a defined average molecular weight range.

"This patent expands our protection of modified pectin solutions and compliments the previously allowed '937 patent described in an earlier press release," said James Rolke, Senior Director of Research and Development at La Jolla and inventor of the technology.

La Jolla Pharmaceutical Company is building a pipeline of drug candidates based on modified pectin, a polysaccharide chemically related to the natural pectin found in plant cell walls. Modified pectin has the ability to bind and sequester the protein galectin-3, over-expression of which has been implicated in a number of human diseases including chronic organ failure and cancer. The modified pectin compositions described in patent '877 may have the advantages of improved therapeutic potency, purity and composition uniformity. The claims allowed in this patent cover such pectin compositions regardless of the intended therapeutic use.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of medical treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. For more information on the Company please visit

Forward Looking Statement Safe Harbor

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on the SEC's web site These risks include, but are not limited to, risks relating to the development of GCS-100, the success and timing of future preclinical and clinical studies of this compound, and potential indications for which GCS-100 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.

Contact Information

  • Company Contact

    George F. Tidmarsh, M.D., Ph.D.
    President & Chief Executive Officer
    La Jolla Pharmaceutical Company
    Phone: (858) 207-4264


    Chester S. Zygmont, III
    Director of Finance
    La Jolla Pharmaceutical Company
    Phone: (858) 207-4264